论文部分内容阅读
美国华盛顿电:据在这里召开的第24届抗微生物制剂和化学治疗学科之间讨论会报道:鉴于细菌对第三代β-内酰胺抗生素耐药性的报道越来越多,制药公司已着手开辟“第四代头孢菌素”的研究。比切姆制药厂的胍丁酰胺(Augmentin),头孢菌素的一种β-内酰胺竞争剂已经出现,制造者在β-内酰胺上所作的努力可以看作是一种新类型青霉素的开端。联合王国比切姆药厂在萨里的研究部报道,此药(BRL366~(50))可抵抗能使很多青霉素类和头孢菌素类灭活的β-内酰胺酶,并且能有效地杀灭绿脓杆菌和其它革兰氏阴性菌。
Washington, United States: According to the 24th Symposium held here between the subject of antimicrobial agents and chemotherapeutics, pharmaceutical companies have begun to address the growing number of bacteria that report third-generation beta-lactam antibiotic resistance Study on “the Fourth Generation Cephalosporins”. Bioclean’s Augmentin, a cephalosporin beta-lactam competitor, has emerged and manufacturers’ efforts on beta-lactam can be seen as the beginning of a new type of penicillin . The research unit in Surrey, United Kingdom, Becheml reported that the drug (BRL 366-50) is resistant to beta-lactamases that inactivate many penicillins and cephalosporins and is effective in killing Pseudomonas aeruginosa and other Gram-negative bacteria.